NCT00224081View on ClinicalTrials.gov

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)

PHASE4CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

May 31, 2006

Conditions
Anemia, Iron-DeficiencyKidney Failure, ChronicHemodialysis
Interventions
DRUG

Sodium ferric gluconate,

Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions

Trial Locations (29)

Unknown

Bakersfield

Glendale

Los Angeles

Santa Rosa

Torrance

Lauderdale Lakes

Tampa

Roswell

Waycross

Crestwood

Wichita

Shreveport

Boston

Kalamazoo

Royal Oak

Columbia

St Louis

North Brunswick

Brooklyn

Minneola

New York

Youngstown

Philadelphia

Chattanooga

Knoxville

Arlington

Houston

San Antonio

Morgantown

Sponsors
All Listed Sponsors
lead

Watson Pharmaceuticals

INDUSTRY

NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) | Biotech Hunter | Biotech Hunter